Remibrutinib Shows Promise in IgE-Mediated Peanut Allergy
A phase 2 trial found that remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, improved tolerance to peanut protein in adults with IgE-mediated peanut allergy.
“Remibrutinib showed superior efficacy versus placebo in adults with peanut allergy, with a favourable safety profile,” the authors concluded.
Among 59 participants, response rates at week 4 increased with dose, reaching an estimated 0.84 at 100 mg twice daily. No serious adverse events were reported.
Reference
Wood R, Tan R, Shah R, et al. Efficacy and safety of remibrutinib, a Bruton’s tyrosine kinase inhibitor, for individuals with IgE-mediated peanut allergy. Presented at: American Academy of Allergy, Asthma, and Immunology annual meeting. February 27-March 2, 2026; Philadelphia, Pennsylvania.
